{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:38:36Z","timestamp":1765456716864,"version":"3.46.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.intimp.2025.115669","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:53:04Z","timestamp":1760248384000},"page":"115669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Resolvin E1-Chemerin receptor 1 axis is dysregulated in critical COVID-19 patients"],"prefix":"10.1016","volume":"167","author":[{"given":"Carolina","family":"Silva-Pereira","sequence":"first","affiliation":[]},{"given":"Marta","family":"Reina-Couto","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Pereira-Terra","sequence":"additional","affiliation":[]},{"given":"Lu\u00edsa","family":"Teixeira-Santos","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Dora","family":"Pinho","sequence":"additional","affiliation":[]},{"given":"Miguel Luz","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udia Camila","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Sarmento","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Tiago","family":"Guimar\u00e3es","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"additional","affiliation":[]},{"given":"S\u00f3nia","family":"Fraga","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Albino-Teixeira","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Roncon-Albuquerque","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Sousa","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2025.115669_bb0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"year":"2023","series-title":"Therapeutics and COVID-19: living guideline, 10 November 2023","author":"WHO","key":"10.1016\/j.intimp.2025.115669_bb0010"},{"key":"10.1016\/j.intimp.2025.115669_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107364","article-title":"Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview","volume":"93","author":"Mohamed Khosroshahi","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115669_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1077236","article-title":"Immune responses in mildly versus critically ill COVID-19 patients","volume":"14","author":"Nasrollahi","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115669_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094545","article-title":"Immune signature of COVID-19: in-depth reasons and consequences of the cytokine storm","volume":"23","author":"Niedzwiedzka-Rystwej","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10223","key":"10.1016\/j.intimp.2025.115669_bb0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China, Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13429","article-title":"Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis","volume":"51","author":"Mulchandani","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2025.115669_bb0040","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jaci.2021.03.047","article-title":"Distinct cytokine profiles associated with COVID-19 severity and mortality","volume":"147","author":"Dorgham","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115669_bb0045","article-title":"Increased circulating cytokines have a role in COVID-19 severity and death with a more pronounced effect in males: a systematic review and Meta-analysis","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40249-023-01086-z","article-title":"Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis","volume":"12","author":"Yin","year":"2023","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.intimp.2025.115669_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105051","article-title":"Targeting inflammation and cytokine storm in COVID-19","volume":"159","author":"Huang","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.115669_bb0060","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1093\/cid\/ciac724","article-title":"Infectious Diseases Society of America guidelines on the treatment and Management of Patients with COVID-19 (September 2022)","volume":"78","author":"Bhimraj","year":"2024","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2025.115669_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121978","article-title":"Programmed cell Death-1\/programmed cell Death-1 ligand as prognostic markers of coronavirus disease 2019 severity","volume":"11","author":"Niedzwiedzka-Rystwej","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0070","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1186\/s13054-020-03374-8","article-title":"Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis","volume":"24","author":"Li","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.intimp.2025.115669_bb0075","first-page":"517","article-title":"Association between hematological parameters and severity of COVID-19 disease","volume":"13","author":"Krishnan","year":"2024","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10555-021-10017-z","article-title":"COVID-19 and cancer: start the resolution!","volume":"41","author":"Barksdale","year":"2022","journal-title":"Cancer Metastasis Rev."},{"issue":"7503","key":"10.1016\/j.intimp.2025.115669_bb0085","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2025.115669_bb0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2019.01.007","article-title":"Mediators of the resolution of the inflammatory response","volume":"40","author":"Sugimoto","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2025.115669_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2023.106762","article-title":"Specialized pro-resolving lipid mediators and resolution of viral diseases","volume":"168","author":"Ferri","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0100","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12931-021-01792-y","article-title":"Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development","volume":"22","author":"Yang","year":"2021","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.intimp.2025.115669_bb0105","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100540R","article-title":"High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients","volume":"35","author":"Archambault","year":"2021","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0110","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1038\/s41598-023-33682-2","article-title":"Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study","volume":"13","author":"Irun","year":"2023","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2025.115669_bb0115","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1161\/CIRCRESAHA.121.319142","article-title":"Disrupted resolution mechanisms favor altered phagocyte responses in COVID-19","volume":"129","author":"Koenis","year":"2021","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.intimp.2025.115669_bb0120","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/infdis\/jiab632","article-title":"Serum levels of Proinflammatory lipid mediators and specialized Proresolving molecules are increased in patients with severe acute respiratory syndrome coronavirus 2 and correlate with markers of the adaptive immune response","volume":"225","author":"Turnbull","year":"2022","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.intimp.2025.115669_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12070619","article-title":"Plasma Oxylipins and their precursors are strongly associated with COVID-19 severity and with immune response markers","volume":"12","author":"Karu","year":"2022","journal-title":"Metabolites"},{"issue":"8","key":"10.1016\/j.intimp.2025.115669_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256226","article-title":"Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients","volume":"16","author":"Palmas","year":"2021","journal-title":"PloS One"},{"issue":"17","key":"10.1016\/j.intimp.2025.115669_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713054","article-title":"Lipid mediators and cytokines\/chemokines display differential profiles in severe versus mild\/moderate COVID-19 patients","volume":"24","author":"Ravindran","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2025.115669_bb0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.2001025","article-title":"Cutting edge: severe SARS-CoV-2 infection in humans is defined by a shift in the serum Lipidome, resulting in dysregulation of eicosanoid immune mediators","volume":"206","author":"Schwarz","year":"2021","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115669_bb0145","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/1568026611109060629","article-title":"Novel anti-inflammatory--pro-resolving mediators and their receptors","volume":"11","author":"Serhan","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"issue":"8","key":"10.1016\/j.intimp.2025.115669_bb0150","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bph.14336","article-title":"Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology","volume":"176","author":"Dalli","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115669_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108753","article-title":"Pro-resolving lipid mediators and therapeutic innovations in resolution of inflammation","volume":"265","author":"Peh","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.115669_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106832","article-title":"Resolvin D2 and its receptor GPR18 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target","volume":"195","author":"Zhao","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2025.115669_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176047","article-title":"The therapeutic potential of resolvins in pulmonary diseases","volume":"958","author":"Centanni","year":"2023","journal-title":"Eur. J. Pharmacol."},{"author":"IUPHAR\/BPS","key":"10.1016\/j.intimp.2025.115669_bb0170"},{"author":"IUPHAR\/BPS","key":"10.1016\/j.intimp.2025.115669_bb0175"},{"issue":"24","key":"10.1016\/j.intimp.2025.115669_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142883","article-title":"The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection","volume":"131","author":"Arnardottir","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2025.115669_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051527","article-title":"Lung inflammation resolution by RvD1 and RvD2 in a receptor-dependent manner","volume":"15","author":"Gao","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.intimp.2025.115669_bb0190","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.0907342107","article-title":"Resolvin D1 binds human phagocytes with evidence for proresolving receptors","volume":"107","author":"Krishnamoorthy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2025.115669_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.112982","article-title":"RvD1binding with FPR2 attenuates inflammation via Rac1\/NOX2 pathway after neonatal hypoxic-ischemic injury in rats","volume":"320","author":"Liu","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.intimp.2025.115669_bb0200","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fphys.2020.00285","article-title":"Resolvin D1 protects against ischemia\/reperfusion-induced acute kidney injury by increasing Treg percentages via the ALX\/FPR2 pathway","volume":"11","author":"Luan","year":"2020","journal-title":"Front. Physiol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115669_bb0205","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.4049\/jimmunol.1501701","article-title":"Resolvin D1 polarizes primary human macrophages toward a Proresolution phenotype through GPR32","volume":"196","author":"Schmid","year":"2016","journal-title":"J. Immunol."},{"issue":"41","key":"10.1016\/j.intimp.2025.115669_bb0210","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2407130121","article-title":"SPMs exert anti-inflammatory and pro-resolving effects through positive allosteric modulation of the prostaglandin EP4 receptor","volume":"121","author":"Alnouri","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.intimp.2025.115669_bb0215","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.20042031","article-title":"Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1","volume":"201","author":"Arita","year":"2005","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.intimp.2025.115669_bb0220","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.117.032801","article-title":"ERV1\/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages","volume":"138","author":"Laguna-Fernandez","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.intimp.2025.115669_bb0225","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/path.4050","article-title":"Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation","volume":"228","author":"Qu","year":"2012","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115669_bb0230","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1161\/HYPERTENSIONAHA.123.21348","article-title":"Resolvin E1\/ChemR23 protects against hypertension and vascular remodeling in angiotensin II-induced hypertensive mice","volume":"80","author":"Zhang","year":"2023","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.intimp.2025.115669_bb0235","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.4049\/jimmunol.0901037","article-title":"Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model","volume":"183","author":"Luangsay","year":"2009","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115669_bb0240","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/molpharm.121.000422","article-title":"Multipathway in vitro pharmacological characterization of specialized Proresolving G protein-coupled receptors","volume":"101","author":"Merlin","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115669_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101597","article-title":"E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition","volume":"59","author":"Serhan","year":"2022","journal-title":"Semin. Immunol."},{"issue":"7395","key":"10.1016\/j.intimp.2025.115669_bb0250","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature11042","article-title":"Infection regulates pro-resolving mediators that lower antibiotic requirements","volume":"484","author":"Chiang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115669_bb0255","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3389\/fimmu.2020.00581","article-title":"Resolvin D1 reduces lung infection and inflammation activating resolution in cystic fibrosis","volume":"11","author":"Isopi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115669_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105877","article-title":"RvD1 ameliorates LPS-induced acute lung injury via the suppression of neutrophil infiltration by reducing CXCL2 expression and release from resident alveolar macrophages","volume":"76","author":"Zhang","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"37","key":"10.1016\/j.intimp.2025.115669_bb0265","doi-asserted-by":"crossref","first-page":"14983","DOI":"10.1073\/pnas.1206641109","article-title":"Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation","volume":"109","author":"El Kebir","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.intimp.2025.115669_bb0270","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4049\/jimmunol.0901809","article-title":"The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury","volume":"184","author":"Seki","year":"2010","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115669_bb0275","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/SHK.0000000000001865","article-title":"Pro-resolving mediator Resolvin E1 restores alveolar fluid clearance in acute respiratory distress syndrome","volume":"57","author":"Luo","year":"2022","journal-title":"Shock"},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0280","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbrc.2010.08.025","article-title":"Protective effect of resolvin E1 on the development of asthmatic airway inflammation","volume":"400","author":"Aoki","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2025.115669_bb0285","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1042\/CS20130623","article-title":"Resolvin E1 promotes resolution of inflammation in a mouse model of an acute exacerbation of allergic asthma","volume":"126","author":"Flesher","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"issue":"8","key":"10.1016\/j.intimp.2025.115669_bb0290","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ni.1627","article-title":"Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation","volume":"9","author":"Haworth","year":"2008","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115669_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002358","article-title":"ChemR23 dampens lung inflammation and enhances anti-viral immunity in a mouse model of acute viral pneumonia","volume":"7","author":"Bondue","year":"2011","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0300","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/CCM.0000000000002014","article-title":"Human Sepsis eicosanoid and Proresolving lipid mediator temporal profiles: correlations with survival and clinical outcomes","volume":"45","author":"Dalli","year":"2017","journal-title":"Crit. Care Med."},{"issue":"21","key":"10.1016\/j.intimp.2025.115669_bb0305","first-page":"6782","article-title":"Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids","volume":"25","author":"Regidor","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115669_bb0310","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13903","article-title":"Alpha-klotho and peritoneal membrane status: a hypothesis generating study","volume":"53","author":"Branco","year":"2023","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0315","doi-asserted-by":"crossref","first-page":"C39","DOI":"10.1152\/ajpcell.00024.2014","article-title":"Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue","volume":"307","author":"Colas","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0320","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00011-024-01964-8","article-title":"Endocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors","volume":"74","author":"Reina-Couto","year":"2025","journal-title":"Inflamm. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115669_bb0325","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00011-022-01682-z","article-title":"Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients","volume":"72","author":"Reina-Couto","year":"2023","journal-title":"Inflamm. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2362.2009.02234.x","article-title":"A catalogue of reporting guidelines for health research","volume":"40","author":"Simera","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115669_bb0335","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.freeradbiomed.2022.01.021","article-title":"MS-based targeted profiling of oxylipins in COVID-19: a new insight into inflammation regulation","volume":"180","author":"Biagini","year":"2022","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115669_bb0340","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4049\/jimmunol.2200079","article-title":"Acetylcholine, fatty acids, and lipid mediators are linked to COVID-19 severity","volume":"209","author":"Perez","year":"2022","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115669_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041181","article-title":"COVID-19, Blood lipid changes, and thrombosis","volume":"11","author":"Farooqui","year":"2023","journal-title":"Biomedicines"},{"issue":"(Suppl 3):001499","key":"10.1016\/j.intimp.2025.115669_bb0350","first-page":"588","article-title":"Inflammation and resolution of inflammation in human acute heart failure","volume":"7","author":"Reina-Couto","year":"2019","journal-title":"Intensive Care Med. Exp."},{"issue":"10","key":"10.1016\/j.intimp.2025.115669_bb0355","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1021\/cr100396c","article-title":"Resolvins and protectins in inflammation resolution","volume":"111","author":"Serhan","year":"2011","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0360","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cell.2013.05.052","article-title":"Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation","volume":"154","author":"Tam","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115669_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108439","article-title":"Icosapent ethyl in cardiovascular prevention: resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis","volume":"247","author":"Back","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115669_bb0370","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4049\/jimmunol.1003456","article-title":"Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1","volume":"186","author":"Rajasagi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115669_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/froh.2022.875047","article-title":"Resolvin E1\u2019s antimicrobial potential against Aggregatibacter Actinomycetemcomitans","volume":"3","author":"Abdullatif","year":"2022","journal-title":"Front Oral Health"},{"issue":"7","key":"10.1016\/j.intimp.2025.115669_bb0380","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.4049\/jimmunol.1600859","article-title":"Resolvin E1 reverses experimental periodontitis and Dysbiosis","volume":"197","author":"Lee","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115669_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions","volume":"14","author":"Carlini","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115669_bb0390","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S2213-2600(21)00539-7","article-title":"Stimulating severe COVID-19: the potential role of GM-CSF antagonism","volume":"10","author":"Leavis","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115669_bb0395","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaci.2018.04.004","article-title":"Dexamethasone induces omega3-derived immunoresolvents driving resolution of allergic airway inflammation","volume":"142","author":"Pyrillou","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"35","key":"10.1016\/j.intimp.2025.115669_bb0400","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302070120","article-title":"Glucocorticoids regulate lipid mediator networks by reciprocal modulation of 15-lipoxygenase isoforms affecting inflammation resolution","volume":"120","author":"Rao","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0405","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1038\/s41467-024-47463-6","article-title":"Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease","volume":"15","author":"Drury","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115669_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.941663","article-title":"Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality","volume":"13","author":"Lavis","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0415","first-page":"174","article-title":"International Union of Basic and Clinical Pharmacology CIII: Chemerin receptors CMKLR1 (Chemerin(1)) and GPR1 (Chemerin(2)) nomenclature","volume":"70","author":"Kennedy","year":"2018","journal-title":"Pharmacology, and Function, Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.intimp.2025.115669_bb0420","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.yexcr.2010.10.023","article-title":"Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual properties","volume":"317","author":"Yoshimura","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"9","key":"10.1016\/j.intimp.2025.115669_bb0425","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2006-08-038844","article-title":"The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues","volume":"109","author":"Parolini","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0430","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.174.1.244","article-title":"Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood","volume":"174","author":"Zabel","year":"2005","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115669_bb0435","doi-asserted-by":"crossref","first-page":"15724","DOI":"10.1038\/s41598-017-15951-z","article-title":"Association of a variant in the gene encoding for ERV1\/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals","volume":"7","author":"Lopez-Vicario","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2025.115669_bb0440","doi-asserted-by":"crossref","first-page":"AB109","DOI":"10.1016\/j.jaci.2009.12.431","article-title":"The formyl peptide receptor 2 (FPR2) is expressed on human eosinophils and its upregulation by dexamethasone (Dex) is abrogated by interleukin 2 and 4","volume":"125","author":"Pazdrak","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115669_bb0445","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bbrc.2006.08.179","article-title":"Glucocorticoid upregulation of the annexin-A1 receptor in leukocytes","volume":"349","author":"Sawmynaden","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2025.115669_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106982","article-title":"Lipoxin-mediated signaling: ALX\/FPR2 interaction and beyond","volume":"197","author":"Sanchez-Garcia","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"19","key":"10.1016\/j.intimp.2025.115669_bb0455","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1111\/bph.15919","article-title":"Formylpeptide receptor 2: nomenclature, structure, signalling and translational perspectives: IUPHAR review 35","volume":"179","author":"Qin","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115669_bb0460","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev-pharmtox-051821-042743","article-title":"Resolution pharmacology: focus on pro-resolving Annexin A1 and lipid mediators for therapeutic innovation in inflammation","volume":"63","author":"Perretti","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115669_bb0465","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001952R","article-title":"Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages","volume":"35","author":"Recchiuti","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2025.115669_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838782","article-title":"Formation, signaling and occurrence of specialized pro-resolving lipid mediators-what is the evidence so far?","volume":"13","author":"Schebb","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:35:19Z","timestamp":1765456519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925016601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":94,"alternative-id":["S1567576925016601"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115669","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolvin E1-Chemerin receptor 1 axis is dysregulated in critical COVID-19 patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115669"}}